Immunotherapy for Alzheimer's disease

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 499-507

  Wisniewski, Thomas ^a   Goñi, Fernando ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Immunomodulation; Tau; Transgenic mice; Vaccination

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BAPINEUZUMAB; CHAPERONE; COMPLEMENT COMPONENT C1Q; CRENEZUMAB; GANTENERUMAB; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYSORBATE 80; PRESENILIN; QS 21; SOLANEZUMAB; TAU PROTEIN; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANTIBODY TITER; BLOOD BRAIN BARRIER; CELLULAR IMMUNITY; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; MICROGLIA; MISSENSE MUTATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TH1 CELL; TH2 CELL; VACCINATION; WHITE MATTER LESION;

ALZHEIMER'S DISEASE; AMYLOID Β; IMMUNOMODULATION; TAU; TRANSGENIC MICE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE;

EID: 84897954317     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.020     Document Type: Review

References (129)

1. J. Gaugler, B. James, T. Johnson, K. Scholz, and J. Weuve Alzheimer's disease facts and figures 2013 2013 Alzheimer's Disease Association on line source: http://www.alz.org/downloads/facts-figures-2013.pdf
2. P.T. Nelson, I. Alafuzoff, E.H. Bigio, C. Bouras, H. Braak, and N. Cairns et al. Correlation of Alzheimer's disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 71 2012 362 381
3. F. Hefti, W.F. Goure, J. Jerecic, K.S. Iverson, P.A. Walicke, and G.A. Krafft The case for soluble Abeta oligomers as a drug target in Alzheimer's disease Trends Pharmacol Sci 34 5 2013 261 266
4. D.L. Castillo-Carranza, C.A. Lasagna-Reeves, and R. Kayed Tau aggregates as immunotherapeutic targets Front Biosci (Schol Ed) 5 2013 426 438
5. K.H. Ashe, and A. Aguzzi Prions, prionoids and pathogenic proteins in Alzheimer disease Prion 7 1 2013 55 59
6. T. Wisniewski, and A. Boutajangout Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models Brain Struct Funct 214 2010 201 218
7. T. Wisniewski, J.A. Chabalgoity, and F. Goni Is vaccination against transmissible spongiform encephalopathies feasible? Rev. Sci. Tech. Off. Int. Epiz. 26 1 2007 243 251 (Pubitemid 47148825)
8. S.N. Ozudogru, and C.F. Lippa Disease modifying drugs targeting beta-amyloid Am J Alzheimer's Dis Other Demen 27 5 2012 296 300
9. T. Wisniewski Active immunotherapy for Alzheimer's disease Lancet Neurol 11 7 2012 571 572
10. J.D. Grill, and J.L. Cummings Current therapeutic targets for the treatment of Alzheimer's disease Expert Rev Neurother 10 5 2010 711 728
11. D. Morgan Immunotherapy for Alzheimer's Disease J Intern Med 269 2011 54 63
12. Y. Huang, and L. Mucke Alzheimer mechanisms and therapeutic strategies Cell 148 6 2012 1204 1222
13. J.M. Ringman, and G. Coppola New genes and new insight from old genes: update on Alzheimer's disease Continuum 19 2 2013 358 371
14. C.T. Loy, P.R. Schofield, A.M. Turner, and J.B. Kwok Genetics of dementia Lancet 2014 In press
15. D.M. Holtzman, E. Mandelkow, and D.J. Selkoe Alzheimer disease in 2020 Cold Spring Harbor Perspect Med 2 11 2012
16. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 2002 353 356 (Pubitemid 34790756)
17. R.E. Tanzi, and L. Bertram Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 4 2005 545 555 (Pubitemid 40269768)
18. T. Wisniewski, E.M. Castaño, A.A. Golabek, T. Vogel, and B. Frangione Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro Am J Pathol 145 5 1994 1030 1035 (Pubitemid 24345650)
19. J. Ma, A. Yee, H.B. Brewer Jr., S. Das, and H. Potter Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments Nature 372 6501 1994 92 94
20. L.V. Johnson, W.P. Leitner, A.J. Rivest, M.K. Staples, M.J. Radeke, and D.H. Anderson The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration PNAS 99 18 2002 11830 11835 (Pubitemid 34994484)
21. K.W. Boyett, G. DiCarlo, P.T. Jantzen, J. Jackson, C. O'Leary, and D. Wilcock et al. Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP + PS1 transgenic mice Neurochem Res 28 1 2003 83 93 (Pubitemid 36173229)
22. H. Potter, and T. Wisniewski Apolipoprotein E: essential catalyst of the Alzheimer amyloid cascade Int J Alzheimer's Dis 2012 2012 489428
23. J. Hardy A hundred years of Alzheimer's disease research Neuron 52 1 2006 3 13 (Pubitemid 44472602)
24. C.A. Lemere, J.K. Blusztajn, H. Yamaguchi, T. Wisniewski, T.C. Saido, and D.J. Selkoe Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol Dis 3 1996 16 32
25. W.C. Mobley, B. Tycko, H. Potter, K. Gardiner, R. Nixon, and K. Iqbal et al. Down syndrome and Alzheimer's disease: common pathways, common goals Alzheimer's Dement 2014 In press
26. T. Wisniewski, and E.M. Sigurdsson Murine models of Alzheimer's disease and their use in developing immunotherapies Biochim Biophys Acta Mol Basis Dis 1802 2010 847 859
27. J. Gotz, F. Chen, D.J. van, and R.M. Nitsch Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils Science 293 5534 2001 1491 1495 (Pubitemid 32807681)
28. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, and R. Kayed et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 3 2003 409 421 (Pubitemid 36937044)
29. M.E. King, H.M. Kan, P.W. Baas, A. Erisir, C.G. Glabe, and G.S. Bloom Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid J Cell Biol 175 4 2006 541 546 (Pubitemid 44790607)
30. C.A. Lemere Immunotherapy for Alzheimer's disease: hoops and hurdles Mol Neurodegener 8 1 2013 36
31. J. Madeo, and M. Frieri Alzheimer's disease and immunotherapy Aging Dis 4 4 2013 210 220
32. S. Oddo, A. Caccamo, L. Tran, M.P. Lambert, C.G. Glabe, and W.L. Klein et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology J Biol Chem 281 3 2006 1599 1604
33. M. Blurton-Jones, and F.M. LaFerla Pathways by which Abeta facilitates tau pathology Curr Alzheimer Res 3 5 2006 437 448 (Pubitemid 46066423)
34. A.C. McKee, I. Carreras, L. Hossain, H. Ryu, W.L. Klein, and S. Oddo et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice Brain Res 1207 2008 225 236
35. J. Naslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, and P. Greengard et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 283 12 2000 1571 1577 (Pubitemid 30161512)
36. G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, and I. Smith et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat Med 2008
37. M. Meyer-Luehmann, J. Coomaraswamy, T. Bolmont, S. Kaeser, C. Schaefer, and E. Kilger et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host Science 313 5794 2006 1781 1784 (Pubitemid 44454153)
38. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, and A. Bayer et al. Long term effects of Aβ42 immunization in Alzheimer's disease: immune response, plaque removal and clinical function Lancet 372 2008 216 223
39. S.A. Small, and K. Duff Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis Neuron 60 4 2008 534 542
40. R.J. Castellani, H.G. Lee, X. Zhu, G. Perry, and M.A. Smith Alzheimer disease pathology as a host response J Neuropathol Exp Neurol 67 6 2008 523 531 (Pubitemid 351787079)
41. J. Shioi, A. Georgakopoulos, P. Mehta, Z. Kouchi, C.M. Litterst, and L. Baki et al. FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta J Neurochem 101 3 2007 674 681 (Pubitemid 46633320)
42. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon Disaggregation of Alzheimer β-amyloid by site-directed mAb PNAS 94 8 1997 4109 4112 (Pubitemid 27180507)
43. B. Solomon Antibody-mediated immunotherapy for Alzheimer's disease Curr Opin Invest Drugs 8 7 2007 519 524 (Pubitemid 47016319)
44. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice Nature 400 1999 173 177 (Pubitemid 29327547)
45. E.M. Sigurdsson, H. Scholtzova, P. Mehta, B. Frangione, and T. Wisniewski Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice Am J Pathol 159 2001 439 447 (Pubitemid 32751074)
46. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, and J. Hardy et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985 (Pubitemid 32101645)
47. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, and S.D. Schmidt et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982 (Pubitemid 32101644)
48. E.M. Sigurdsson, E.L. Knudsen, A. Asuni, D. Sage, F. Goni, and D. Quartermain et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives J Neurosci 24 2004 6277 6282 (Pubitemid 38944217)
49. A. Asuni, A. Boutajangout, H. Scholtzova, E. Knudsen, Y. Li, and D. Quartermain et al. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice Eur J Neurosci 24 2006 2530 2542 (Pubitemid 44726765)
50. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 8 2000 916 919 (Pubitemid 30644751)
51. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease PNAS 98 15 2001 8850 8855 (Pubitemid 32678116)
52. C.A. Lemere, R. Maron, D.J. Selkoe, and H.L. Weiner Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease DNA Cell Biol 20 11 2001 705 711 (Pubitemid 34072837)
53. E.M. Sigurdsson, H. Scholtzova, P. Mehta, B. Frangione, and T. Wisniewski Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice Am J Pathol 159 2001 439 447 (Pubitemid 32751074)
54. E.M. Sigurdsson, B. Frangione, and T. Wisniewski Immunization for Alzheimer's disease Drug Dev Res 56 2002 135 142 (Pubitemid 35014936)
55. T. Wisniewski, and B. Frangione Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease Brain Pathol 15 2005 72 77 (Pubitemid 40224069)
56. A.J. Bayer, R. Bullock, R.W. Jones, D. Wilkinson, K.R. Paterson, and L. Jenkins et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD Neurology 64 2005 94 101 (Pubitemid 40082943)
57. M. Pride, P. Seubert, M. Grundman, M. Hagen, J. Eldridge, and R.S. Black Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis Neurodegener Dis 5 3-4 2008 194 196 (Pubitemid 351347848)
58. T. Wisniewski Practice point commentary on Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial Nat Clin Prac Neurol 1 2005 84 85
59. D. Boche, and J.A. Nicoll The role of the immune system in clearance of Aβ from the brain Brain Pathol 18 2 2008 267 278 (Pubitemid 351430403)
60. S. Bombois, C.A. Maurage, M. Gompel, V. Deramecourt, M.A. kowiak-Cordoliani, and R.S. Black et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia Arch Neurol 64 4 2007 583 587 (Pubitemid 46588350)
61. I. Ferrer, R.M. Boada, M.L. Sanchez Guerra, M.J. Rey, and F. Costa-Jussa Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease Brain Pathol 14 2004 11 20 (Pubitemid 38200585)
62. E. Masliah, L. Hansen, A. Adame, L. Crews, F. Bard, and C. Lee et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 64 2005 129 131 (Pubitemid 40082949)
63. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nat Med 9 2005 448 452
64. J.A. Nicoll, E. Barton, D. Boche, J.W. Neal, I. Ferrer, and P. Thompson et al. Abeta species removal after abeta42 immunization J Neuropathol Exp Neurol 65 11 2006 1040 1048 (Pubitemid 44684661)
65. M. Sadowski, and T. Wisniewski Disease modifying approaches for Alzheimer's pathology Curr Pharm Des 13 19 2007 1943 1954 (Pubitemid 47040494)
66. C. Hock, U. Konietzko, A. Paspassotiropoulos, A. Wollmer, J. Streffer, and R.C. von Rotz et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease Nat Med 8 2002 1270 1276
67. C. Hock, U. Konietzko, J.R. Straffer, J. Tracy, A. Signorell, and B. Muller-Tillmanns et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554 (Pubitemid 36645030)
68. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, and N.C. Fox et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interupted trial Neurology 64 2005 1553 1562 (Pubitemid 40617691)
69. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, and T. Dumortier et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 11 7 2012 597 604
70. J.M. Ryan, and M. Grundman Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing J Alzheimer's Dis 17 2 2009 243
71. A. Schneeberger, M. Mandler, O. Otawa, W. Zauner, F. Mattner, and W. Schmidt Development of AFFITOPE vaccines for Alzheimer's disease (AD) - from concept to clinical testing J Nutr Health Aging 13 3 2009 264 267
72. T.C. Saido, T. Iwatsubo, D.M. Mann, H. Shimada, Y. Ihara, and S. Kawashima Dominant and differential deposition of distinct beta-amyloid peptide species, Aβ N3(pE), in senile plaques Neuron 14 2 1995 457 466
73. J.L. Frost, K.X. Le, H. Cynis, E. Ekpo, M. Kleinschmidt, and R.M. Palmour et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models Am J Pathol 183 2 2013 369 381
74. R.B. DeMattos, J. Lu, Y. Tang, M.M. Racke, C.A. DeLong, and J.A. Tzaferis et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice Neuron 76 5 2012 908 920
75. A. Muhs, D.T. Hickman, M. Pihlgren, N. Chuard, V. Giriens, and C. Meerschman et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice PNAS 104 23 2007 9810 9815 (Pubitemid 47175348)
76. T. Wisniewski, and U. Konietzko Amyloid-β immunization for Alzheimer's disease Lancet Neurol 7 9 2008 805 811
77. J. Moreth, C. Mavoungou, and K. Schindowski Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing 10 1 2013 18
78. M.R. Farlow, and J.R. Brosch Immunotherapy for Alzheimer's disease Neurol Clin 31 3 2013 869 878
79. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, and D. Games et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology PNAS 100 4 2003 2023 2028 (Pubitemid 36254567)
80. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 24 2009 2061 2070
81. R. Sperling, S. Salloway, D.J. Brooks, D. Tampieri, J. Barakos, and N.C. Fox et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 11 3 2012 241 249
82. M. Farlow, S.E. Arnold, C.H. Van Dyck, P.S. Aisen, B.J. Snider, and A.P. Porsteinsson et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease Alzheimer's Dement 8 4 2012 261 271
83. B. Bohrmann, K. Baumann, J. Benz, F. Gerber, W. Huber, and F. Knoflach et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta J Alzheimer's Dis 28 1 2012 49 69
84. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, and D.J. Brooks et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch Neurol 69 2011 198 207
85. O. Adolfsson, M. Pihlgren, N. Toni, Y. Varisco, A.L. Buccarello, and K. Antoniello et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta J Neurosci 32 28 2012 9677 9689
86. H. Fillit, G. Hess, J. Hill, P. Bonnet, and C. Toso IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders Neurology 73 3 2009 180 185
87. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, and R.W. Lent et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol Aging 30 11 2009 1728 1736
88. G. Shayan, B. Adamiak, N.R. Relkin, and K.H. Lee Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy Electrophoresis 33 13 2012 1975 1979
89. R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, and S. Forster et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial Lancet Neurol 12 3 2013 233 243
90. F. Panza, V. Frisardi, V. Solfrizzi, B.P. Imbimbo, G. Logroscino, and A. Santamato et al. Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies Immunotherapy 4 2 2012 213 238
91. D. Puzzo, L. Privitera, E. Leznik, M. Fa, A. Staniszewski, and A. Palmeri et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus J Neurosci 28 53 2008 14537 14545
92. M.L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, B.P. De, and V. Bruno et al. Beta-amyloid monomers are neuroprotective J Neurosci 29 34 2009 10582 10587
93. S.J. Soscia, J.E. Kirby, K.J. Washicosky, S.M. Tucker, M. Ingelsson, and B. Hyman et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide PLoS One 5 3 2010 e9505
94. Y. Yoshiyama, V.M. Lee, and J.Q. Trojanowski Therapeutic strategies for tau mediated neurodegeneration J Neurol Neurosurg Psychiatry 84 7 2013 784 795
95. E.M. Sigurdsson Tau immunotherapy and imaging Neurodegener Dis 2014 In press
96. E.M. Sigurdsson Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies J Alzheimer's Dis 15 2 2008 157 168
97. W. Noble, C.J. Garwood, and D.P. Hanger Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding Prion 3 2 2009
98. R. Kayed, and G.R. Jackson Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders Curr Opin Immunol 21 3 2009 359 363
99. H. Braak, and T.K. Del The pathological process underlying Alzheimer's disease in individuals under thirty Acta Neuropathol 121 2 2011 171 181
100. A. Elobeid, H. Soininen, and I. Alafuzoff Hyperphosphorylated tau in young and middle-aged subjects Acta Neuropathol 123 1 2012 97 104
101. P.V. Arriagada, J.H. Growdon, E.T. Hedley-Whyte, and B.T. Hyman Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurol 42 3 Pt 1 1992 631 639
102. C. Bancher, H. Braak, P. Fischer, and K.A. Jellinger Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients Neurosci Lett 162 1-2 1993 179 182 (Pubitemid 23347976)
103. R.D. Terry The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis J Neuropath Exp Neurol 55 10 1996 1023 1025 (Pubitemid 26338013)
104. A.A. Asuni, A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements J Neurosci 27 34 2007 9115 9129 (Pubitemid 47312068)
105. J. Eidenmuller, T. Fath, T. Maas, M. Pool, E. Sontag, and R. Brandt Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein Biochem J 357 Pt 3 2001 759 767 (Pubitemid 32735156)
106. T. Fath, J. Eidenmuller, and R. Brandt Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease J Neurosci 22 22 2002 9733 9741 (Pubitemid 35332856)
107. A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model J Neurosci 30 49 2010 16559 16566
108. E. Masliah, E. Rockenstein, A. Adame, M. Alford, L. Crews, and M. Hashimoto et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease Neuron 46 6 2005 857 868 (Pubitemid 40805347)
109. E.E. Congdon, J. Gu, H.B. Sait, and E.M. Sigurdsson Antibody uptake into neurons occurs primarily via clathrin dependent Fcgamma receptor endocytosis, and is a prerequisite for acute tau clearance J Biol Chem 288 2013 35452 35465
110. F. Clavaguera, T. Bolmont, R.A. Crowther, D. Abramowski, S. Frank, and A. Probst et al. Transmission and spreading of tauopathy in transgenic mouse brain Nat Cell Biol 11 7 2009 909 913
111. P.H. Ren, J.E. Lauckner, I. Kachirskaia, J.E. Heuser, R. Melki, and R.R. Kopito Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates Nat Cell Biol 11 2 2009 219 225
112. H. Rosenmann, N. Grigoriadis, D. Karussis, M. Boimel, O. Touloumi, and H. Ovadia et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein Arch Neurol 63 10 2006 1459 1467 (Pubitemid 44547559)
113. L. Rozenstein-Tsalkovich, N. Grigoriadis, A. Lourbopoulos, E. Nousiopoulou, I. Kassis, and O. Abramsky et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation Exp Neurol 248 2013 451 456
114. A. Boutajangout, J. Ingadottir, P. Davies, and E.M. Sigurdsson Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain J Neurochem 118 4 2011 658 667
115. X. Chai, S. Wu, T.K. Murray, R. Kinley, C.V. Cella, and H. Sims et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression J Biol Chem 286 39 2011 34457 34467
116. K. Yanamandra, N. Kfoury, H. Jiang, T.E. Mahan, S. Ma, and S.E. Maloney et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo Neuron 80 2 2013 402 414
117. C. d'Abramo, C.M. Acker, H.T. Jimenez, and P. Davies Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity PLoS One 8 4 2013 e62402
118. C monoclonal antibody infusion as a novel treatment for Aβ oligomer cognitive cognitive deficits BMC Neurosci 11 2010 130
119. A.E. Barry, I. Klyubin, J.M. Mc Donald, A.J. Mably, M.A. Farrell, and M. Scott et al. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein J Neurosci 31 20 2011 7259 7263
120. E.B. Lee, L.Z. Leng, B. Zhang, L. Kwong, J.Q. Trojanowski, and T. Abel et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice J Biol Chem 281 7 2006 4292 4299 (Pubitemid 43847859)
121. N. Moretto, A. Bolchi, C. Rivetti, B.P. Imbimbo, G. Villetti, and V. Pietrini et al. Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide J Biol Chem 282 15 2007 11436 11445 (Pubitemid 47100761)
122. G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, and N. Movsesyan et al. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers J Biol Chem 282 31 2007 22376 22386 (Pubitemid 47267321)
123. M.P. Lambert, P.T. Velasco, L. Chang, K.L. Viola, S. Fernandez, and P.N. Lacor et al. Monoclonal antibodies that target pathological assemblies of Abeta J Neurochem 100 1 2007 23 35 (Pubitemid 46085837)
124. M.P. Lambert, P.T. Velasco, K.L. Viola, and W.L. Klein Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins CNS Neurol Disord Drug Targets 8 1 2009 65 81
125. T. Wisniewski, F. Prelli, H. Scholtzova, E. Chung, P.D. Mehta, and R. Kascsak et al. Immunotherapy targeting abnormal protein conformation Alzheimer's Dement 5 4, Suppl. 1 2009 P113
126. R. Vidal, B. Frangione, A. Rostagno, S. Mead, T. Revesz, and G. Plant et al. A stop-codon mutation in the BRI gene associated with familial British dementia Nature 399 6738 1999 776 781 (Pubitemid 29293172)
127. A. Rostagno, Y. Tomidokoro, T. Lashley, D. Ng, G. Plant, and J. Holton et al. Chromosome 13 dementias Cell Mol Life Sci 62 16 2005 1814 1825 (Pubitemid 41188521)
128. F. Goni, F. Prelli, Y. Ji, H. Scholtzova, J. Yang, and Y. Sun et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease PLoS One 5 10 2010 e13391
129. F. Goni, K. Herline, D. Peyser, K. Wong, Y. Ji, and Y. Sun et al. Immunomodulation targeting both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models J Neuroinflammation 10 2013 150